As psychedelics have become more popular and research has found the numerous benefits these substances potentially hold, microdosing has increased in popularity as well. For those who may not have come across the term, it refers to the practice of consuming low doses of psychedelic substances to improve an individual’s productivity, creativity or mood.
While this practice has been heralded by some as effective, scientific evidence to back these claims is yet to be discovered. Now a team of researchers led by the Maastricht University and Imperial College London have investigated the practice and published its findings in the “Journal of Psychopharmacology,” tackling questions such as whether the claims of the benefits microdosing provides are likely and if the process is legal and safe.
The objective of the researchers’ report is to provide a framework for future research in the field as well as provide evidence on whether microdosing psychedelics such as psilocybin and LSD can impact an individual’s health and if there are any dangers associated with this practice.
Prof. David Nutt, the review’s senior author and the Imperial College London’s chair in Neuro-psychopharmacology, stated that there is no scientific consensus on what microdosing entails, its possible health effects, how often individuals can microdose or what amount adds up to a microdose.
In their report, the researchers define microdosing as the practice of consuming repeated small doses of psychedelic drugs at levels that do not hinder an individual’s normal functioning in an attempt to boost emotional or cognitive processes and enhance an individual’s well-being. The researchers state that the frequency of consumption and the potency of the substances as well as their strength may vary. In addition, they note that while most anecdotal reports on microdosing focus on positive accounts, future research should also look into potential risks associated with the practice.
With regards to safety, the researchers claim that the evidence for psilocybin microdosing in the long term is lacking in both animals and humans, adding that there also exists evidence linking the practice to cardiovascular risks. Apart from this, the authors also report that the regulation and legality of psychedelic substances present a barrier for research because most of the drugs in this field, including DMT, LSD and psilocybin, are still classified under Schedule 1 of the Controlled Substances Act and Schedule I under the UN Convention.
Despite these issues, researchers are hopeful that clinical studies on these substances will be conducted in order to determine whether the claims of microdosing can be supported.
In the meantime, companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are developing therapeutic products targeting mental health issues, which are expected to increase.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.